| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2615cd73a750bed25d63085b90cdb827 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 |
| filingDate |
2022-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2fb4d370708ad93f0b91490426ae525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_948df085d436957f332921168d3b45ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bbbd1100dfb759980e2376173888321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cd2ea37921ef311d7339a6bbcaf9558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7249c6d0de5162292db5588cb8e1ca68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81aed03e6d4b2e83f003850f9106a1ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_164770f38380094ee3ff5c93cdeb834a |
| publicationDate |
2022-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022179592-A1 |
| titleOfInvention |
Combination therapeutic drug for acute myeloid leukemia |
| abstract |
Disclosed are a drug and method for treating acute myeloid leukemia by means of combined administration of a multi-target kinase inhibitor compound I or a pharmaceutically acceptable salt thereof with daunorubicin and cytarabine. The combination of compound I or the pharmaceutically acceptable salt thereof with daunorubicin and cytarabine can significantly inhibit the proliferation of human leukemia cells MV-4-11 and MOLM-13, produces a synergistic effect, and has a combined efficacy which is better than that of a scheme only using daunorubicin and cytarabine, and treated patients will have a longer survival period. The potential of the combination therapeutic scheme in prognosis improvement is much greater than the risk of potential toxicity thereof, and the scheme has good clinical application prospects. |
| priorityDate |
2021-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |